Icon (NASDAQ:ICLR) Issues FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 10.000-11.000 for the period, compared to the consensus earnings per share estimate of 10.380. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. TD Cowen upped their price target on shares of Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Bank of America raised their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a report on Thursday, June 25th. Leerink Partners set a $145.00 price target on Icon in a research note on Thursday, May 28th. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Finally, DA Davidson set a $164.00 price target on Icon in a research report on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $173.19.

Icon Price Performance

NASDAQ:ICLR opened at $170.00 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14. The company has a 50-day moving average of $145.31 and a 200-day moving average of $136.78. Icon has a 52 week low of $66.57 and a 52 week high of $211.00. The company has a market capitalization of $13.02 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 8.45 and a beta of 1.22.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.07. Icon had a net margin of 5.35% and a return on equity of 8.73%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter last year, the company earned $3.43 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Icon will post 9.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Icon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. raised its holdings in shares of Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after buying an additional 329,266 shares during the last quarter. Vident Advisory LLC raised its position in shares of Icon by 47.2% in the 4th quarter. Vident Advisory LLC now owns 41,059 shares of the medical research company’s stock valued at $7,482,000 after acquiring an additional 13,175 shares during the period. NewEdge Advisors LLC boosted its stake in Icon by 8.6% during the 4th quarter. NewEdge Advisors LLC now owns 1,309 shares of the medical research company’s stock worth $238,000 after acquiring an additional 104 shares during the last quarter. Moore Capital Management LP grew its holdings in shares of Icon by 96.7% in the 4th quarter. Moore Capital Management LP now owns 57,190 shares of the medical research company’s stock valued at $10,421,000 after buying an additional 28,116 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of Icon by 12.7% in the 4th quarter. Janus Henderson Group PLC now owns 248,279 shares of the medical research company’s stock valued at $45,241,000 after buying an additional 28,008 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.